PER-009-19尚未招募未知
A MULTICENTER, MULTINATIONAL, PROSPECTIVE, INTERVENTIONAL, SINGLE-ARM, PHASE IV STUDY EVALUATING THE CLINICAL EFFICACY AND SAFETY OF 26 WEEKS OF TREATMENT WITH INSULIN GLARGINE 300 U/ML (GLA-300) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNCONTROLLED ON BASAL INSULI
Sanofi Aventis Recherche & Development,0 个研究点目标入组 26 人开始时间: 2019年6月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •I 01. Participants must be >18 years of age (inclusive), at the time of signing the informed
- •Type of participant and disease characteristics
- •I 02. Participants with T2DM.
- •I 03. Participants on standard of care” basal insulin therapy (including Gla-100, detemir,
- •degludec, NPH insulin), administered once or twice daily, as per labeling for at least
- •6 months prior to screening visit, with or without oral agents (metformin, sulfonylurea,
- •thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinide, α-glucosidase inhibitor) and
- •with or without use of a GLP-1 receptor agonist, approved for using with insulin.
- •I 04. HbA1c between 7.5% (58 mmol/mol) and 10% (86 mmol/mol) inclusive, during screening.
- •I 05. Median of the last 3 consecutive fasting SMPG values prior to baseline, or at least
- •2 fasting SMPG values in the week prior to baseline >130 mg/dL.
- •I 06. Male or Female
- •- Female participants: A female participant is eligible to participate if she is not pregnant
- •(see Appendix 4 [Section 10.4]), not breastfeeding, and at least 1 of the following
- •conditions applies:
- •- Not a woman of childbearing potential (WOCBP) as defined in Appendix 4
- •(Section 10.4).
- •- A WOCBP who agrees to follow the contraceptive guidance in Appendix 4
- •(Section 10.4) during the intervention period and for at least 1 week after the last dose
- •of study intervention (ie, until Week 27).
- •Informed Consent
- •I 07. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1.3)
- •which includes compliance with the requirements and restrictions listed in the informed
- •consent form (ICF) and in this protocol.
排除标准
- •Medical conditions
- •E 01. Any clinically significant abnormality identified either in medical history or during
- •screening evaluation (eg, physical examination, laboratory tests, electrocardiogram, vital
- •signs) or any AEs during screening period which in judgment of the Investigator would
- •preclude safe completion of the study or constrains efficacy assessment.
- •E 02. Known presence of factors that interfere with the HbA1c measurement (eg, specific
- •hemoglobin variants, hemolytic anemia) compromising the reliability of HbA1c
- •assessment or medical conditions that affect interpretation of HbA1c results (eg, blood
- •transfusion or severe blood loss in the last 3 months prior to baseline, any condition that
- •shortens erythrocyte survival).
- •E 03. History of severe hypoglycemia requiring emergency room admission or hospitalization
- •within 3 months prior to screening visit.
- •E 04. Proliferative retinopathy or maculopathy requiring treatment according to the Investigator.
- •Prior/concomitant therapy
- •E 05. Unstable basal insulin regimen in the last 8 weeks prior to screening visit (ie, type of
- •insulin and time/frequency of the injection, insulin doses [variation more than ±20%]).
- •E 06. Treatment with insulin other than basal insulin: mixed insulin (premixes), rapid insulin,
- •and fast acting insulin analogues in the last 6 months before screening visit (use ≤10 days
- •in relation to hospitalization or an acute illness is accepted).
- •E 07. Use of non-insulin antidiabetic drugs other than those listed in inclusion criteria.
- •E 08. Change in existing dose or initiation of new, non-insulin antidiabetic drugs in the 8 weeks
- •prior to screening visit.
- •E 09. Use of systemic glucocorticoids (excluding topical application or inhaled forms) for
- •2 weeks or more within 8 weeks prior to screening visit.
- •E 10. Likelihood to require treatment prohibited by the protocol during the study.
- •Prior/concurrent clinical study experience
- •E 11. Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is
- •longer, prior to screening visit or concomitant enrollment in any other clinical study
- •involving an investigational study treatment.
- •Diagnostic Assessments
- •Not applicable
- •Other exclusions
- •E 12. Any specific situation during study implementation/course that may raise ethics
- •considerations.
- •E 13. History of hypoglycemia unawareness.
- •E 14. Known hypersensitivity/intolerance to Gla-300 or any IMP excipients.
- •E 15. History of drug or alcohol abuse within 6 months prior to screening visit.
- •Additional criteria at the end of the screening period
- •E 16. Participants unwilling or unable to comply with study procedures as outlined in the
- •E 17. Participants who withdraw consent during the screening (starting from signed ICF).
研究者
相似试验
尚未招募
4 期
A study to find out if Toujeo is safe and efficient in patients with Ty 2 DM, who previously were taking another basal insulin but wasnt efficient. A basal insulin is secreted continuously during the day into the bloodstream from SC depot, when a natural secretion from pancreas is reduced.CTRI/2019/08/020701SanofiAventis Groupe
Unknown
4 期
A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insuliPatients with Type 2 diabetes mellitus uncontrolled on basal insulinK63.9DiabetesLBCTR2019040212Sanofi11
进行中（未招募）
1 期
Study of 4 regimens of Group B Streptococcus vaccine (GBS-NN/NN2) in pregnant women.EUCTR2021-003214-40-DKMinervaX Aps270
已完成
3 期
Comparative study of efficacy and safety of Relipoietin and of medicinal drug Eprex® in the treatment of anemia in patients with chronic kidney disease on hemodialysisCTRI/2013/01/003325OK BETA PHARMACEUTICALS I PVT LTD50
已完成
4 期
MULTINATIONAL, MULTICENTRE, PROSPECTIVE, LONG-TERM SAFETY AND EFFICACY FOLLOW-UP STUDY AFTER AUTOLOGOUS CULTIVATED LIMBAL STEM CELLS TRANSPLANTATION (ACLSCT) FOR RESTORATION OF CORNEAL EPITHELIUM IN PATIENTS WITH LIMBAL STEM CELL DEFICIENCY DUE TO OCULAR BURNSNL-OMON49307Holostem Terapie Avenzate S.r.l4